Simple test could predict dementia 15 years early: 'Breakthrough' in fight against UK's biggest killer
Getty Images
The blood test could be "seamlessly integrated into the NHS", experts say.
A blood test that could predict dementia up to 15 years before diagnosis could improve the lives of thousands of Britons, researchers say.
Scientists have identified 11 proteins that they say can predict a future diagnosis of dementia with 90 percent accuracy.
These proteins could be identified via a simple blood test that could replace invasive procedures and get effective new drugs to Britons faster, the study's researchers say.
The researchers, from the University of Warwick and Fudan University in China, described their findings, published in the journal Nature Aging, as a “breakthrough”.
The test could replace invasive procedures and get effective new drugs to Britons faster
Getty Images
What did they find out?
For the study, thought to be the largest of its kind, the researchers looked at data from more than 50,000 healthy people from UK Biobank, which holds medical and lifestyle records of more than half a million Britons.
They analysed the blood samples from this group collected between 2006 and 2010.
Over a follow-up period of 10 to 15 years, more than 1,400 people went on to develop dementia.
By analysing more than 1,400 different proteins in the blood and using artificial intelligence, the researchers found 11 proteins that could accurately predict dementia up to 15 years before diagnosis.
These proteins, found in the liquid component of blood known as the plasma, are markers for the biological changes that happen in people who have dementia or Alzheimer’s disease.
One such protein – known as GFAP – has previously been identified as a potential biomarker in smaller studies.
The implications
Professor Jianfeng Feng, from the University of Warwick’s department of computer science, said this test “could be seamlessly integrated into the NHS and used as a screening tool by GPs”.
He said: “A notable advantage of plasma protein analysis is that it merely necessitates routine blood tests, similar to those conducted during regular hospital visits or health checks.
LATEST DEVELOPMENTS
'Left me to rot!' Furious Briton demands Sunak 'look him in the eye' and give him straight answer on Covid vaccine harm
Alaskapox breaks out in US as horrendous images of lesions on body emergeFish lovers rejoice! Researchers say they have discovered best type of fish to lower high cholesterol
The blood test could be 'seamlessly integrated into the NHS', researchers say
Getty Images
“This simplicity offers a considerable edge over more invasive procedures like lumbar punctures, especially where the targeting population are healthy individuals.”
Commenting on the study, Dr Richard Oakley, associate director of research and innovation at Alzheimer’s Society, said: “This research looked at proteins in the blood of healthy individuals and followed them up 15 years later and found a common set of proteins in those that went on to develop dementia.
“It’s very early days and lots more work is needed but this could lay the groundwork for the early prediction of dementia and teach us more about how to provide an early and accurate diagnosis.
“What we need now are blood tests that work in a real-world setting and that can accurately diagnose dementia when someone is starting to show symptoms.
“This is why we’re working with Alzheimer’s Research UK on the Blood Biomarker Challenge which will revolutionise the way dementia is diagnosed.
“The project, which is possible thanks to £5 million in funding raised by players of People’s Postcode Lottery, will gather the information needed to introduce a blood test for dementia into UK healthcare systems.”
Dr Sheona Scales, director of research at Alzheimer’s Research UK, added: “We have seen some fantastic progress in the development of blood tests for Alzheimer’s over the last few months.
“This new study adds to the growing body of evidence that looking at levels of certain proteins in the blood of healthy people could accurately predict dementia before symptoms develop.
“Further studies are needed to understand how these tests and predictive models work with data from more diverse populations.
“The key proteins hallmarks of Alzheimer’s disease – amyloid and tau – also were not included in the analysis, so we don’t know how these proteins would affect the prediction model.
“And, even when tests show promise in studies like this, they still need to go through regulatory approval before they can be used in a healthcare setting.”